# ARV-102 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/arv-102

> ARV-102, sponsored by ARVINAS, INC. (ARVN): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: year only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ARV-102 |
| Codes | ARV-102 |
| Sponsor | ARVINAS, INC. (ARVN) https://sec-api.dev/companies/arvn/catalysts |
| Indications | [parkinson's disease](https://sec-api.dev/indications/parkinson-s-disease), progressive supranuclear palsy, pd and initiate the mad portion of the phase 1 clinical trial in patients with pd in 2025, pd in 2026 |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### 2025: trial start

- Status: scheduled. Date confidence: year. Stage: 1. Indication: PD and initiate the MAD portion of the Phase 1 clinical trial in patients with PD in 2025.
- First seen 2025-02-11, last confirmed 2025-02-11.
- SEC Form 10-K (accession 0001655759-25-000016): "We plan to complete enrollment and present initial data from the ongoing SAD Phase 1 clinical trial of ARV-102 in patients with PD and initiate the MAD portion of the Phase 1 clinical trial in patients with PD in 2025." https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/arvn-20241231.htm

### January 10, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1. Indication: Parkinson's disease.
- First seen 2025-01-10, last confirmed 2025-01-10.
- SEC Form 8-K (accession 0001655759-25-000004): "The Company also announced that it recently initiated a Phase 1 clinical trial with PROTAC leucine-rich repeat kinase 2 ("LRRK2") protein degrader ARV-102 in patients with Parkinson's disease and that, in 2025, the Company plans to:" https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/arvn-20250110.htm

### February 11, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1. Indication: Parkinson's disease.
- First seen 2025-02-11, last confirmed 2025-02-11.
- Press release filed with the SEC (EX-99) (accession 0001655759-25-000008): "- Initiated a Phase 1 trial with ARV-102 in patients with Parkinson's disease and announced Phase 1 data in healthy volunteers has been accepted for oral presentation at Alzheimer's Disease/Parkinson's Disease congress -" https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/arvn-20250211xexx991.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-08-06, last confirmed 2025-08-06.
- SEC Form 10-Q (accession 0001655759-25-000139): "We expect to share initial data from this SAD cohort of the Phase 1 clinical trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/arvn-20250630.htm

### 2026: interim data readout

- Status: scheduled. Date confidence: year. Stage: 1. Indication: Parkinson's disease.
- First seen 2025-10-06, last confirmed 2025-11-05.
- SEC Form 8-K (accession 0001628280-25-044212): "The Company plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson's disease (ARV-102-103) in 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-20251005.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-044212): "Arvinas plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial in patients with Parkinson's disease (ARV-102-103) in 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-mdsx2025.htm
- SEC Form 10-Q (accession 0001628280-25-049527): "We plan to present initial data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with PD in 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/arvn-20250930.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1. Indication: progressive supranuclear palsy.
- First seen 2025-08-06, last confirmed 2026-05-12.
- SEC Form 8-K (accession 0001628280-26-019026): "Pending regulatory feedback, the Company intends to initiate a Phase 1b clinical trial in progressive supranuclear palsy in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while it continues to evaluate development options for ARV-102 in Parkinson's disease." https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arvn-20260318.htm
- SEC Form 8-K (accession 0001628280-26-019026): "This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential of ARV-102; the Company's plans to continue investigation of ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction; and the Company's intention, pending regulatory feedback, to initiate a Phase 1b clinical trial in progressive supranuclear palsy in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while it continues to evaluate development options for ARV-102 in Parkinson's disease." https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arvn-20260318.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-019026): "Building on these results, and pending regulatory feedback, we intend to initiate a Phase 1b clinical trial in PSP in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while we continue evaluating development options for ARV-102 in Parkinson's disease."" https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arv-102datapresentationp.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-019026): "ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson's disease and Arvinas plans to initiate a Phase 1b clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arv-102datapresentationp.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-010865): "ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson's disease and Arvinas plans to initiate a Phase 1b clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828026010865/q42025earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-049235): "ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson's disease and Arvinas plans to initiate a Phase 1b clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/q32025earningsrelease.htm
- SEC Form 8-K (accession 0001628280-25-044212): "Pending data from the multiple dose cohort and investigational new drug clearance, the Company intends to initiate a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-20251005.htm
- SEC Form 10-K (accession 0001628280-26-011226): "We also believe these data support development in PSP, and pending regulatory feedback, we plan to initiate a Phase 1b clinical trial of ARV-102 in patients with PSP in the first half of 2026 and have the potential to initiate a registrational trial of ARV-102 in PSP in late 2026, pending regulatory feedback." https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/arvn-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-049527): "Pending regulatory feedback, we plan to initiate a Phase 1b clinical trial of ARV-102 in patients with PSP in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/arvn-20250930.htm
- SEC Form 10-Q (accession 0001655759-25-000139): "We also plan to initiate a Phase 1b clinical trial of ARV-102 in patients with PSP in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/arvn-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-044212): "Pending data from the multiple dose cohort and investigational new drug (IND) clearance, Arvinas intends to initiate a Phase 1b trial in patients with progressive supranuclear palsy in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-mdsx2025.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-033875): "ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson's disease and Arvinas plans to initiate a Phase 1b, and potentially registrational Phase 2, clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in 2H 2026." https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/q12026earningsrelease.htm

## Same indication

- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Rexaceract](https://sec-api.dev/pdufa/rexaceract) (GANX)
- [Juvmo (tavapadon)](https://sec-api.dev/pdufa/tavapadon) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/arv-102.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARV-102 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/arv-102

```bibtex
@misc{secapidev_pdufa_arv_102_20261116,
  title        = {ARV-102 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/arv-102}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_arv_102_20261116","title":"ARV-102 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/arv-102","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
